top of page
Primary Research – Proof of Market

Inventya Ltd (an independent market research organization) had been commissioned by UroPharma to conduct a primary research in 2015, this study funded by 


This research study revealed that there are significant concerns with the current drug treatments for Urinary Incontinence (UI) and Overactive Bladder (OAB). The research revealed that side effects/low tolerability was perceived to be the most common drawback of oral antimuscarinics, the accepted first line treatments for OAB. Almost 90% of healthcare professional respondents who were asked responded that they were likely to use or recommend UroPharma’s dtb-instilla.


The full independent Proof of Market Report conducted by Inventya Ltd, including the primary and secondary research is available upon request.

bottom of page